Open access
Open access
Powered by Google Translator Translator

HIV

Overview of SARS-CoV-2 infection in adults living with HIV – Low CD4 cell counts, or untreated HIV infection is associated a more severe clinical course

28 Apr, 2021 | 08:32h | UTC

Overview of SARS-CoV-2 infection in adults living with HIV – The Lancet HIV

 

Commentary on Twitter

 


Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

2 Apr, 2021 | 09:15h | UTC

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: ART in pregnant women living with HIV – The Lancet

 


Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

21 Mar, 2021 | 21:34h | UTC

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition – New England Journal of Medicine (link to abstract – $ for full-text)

 


WHO Guideline: Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring

18 Mar, 2021 | 08:55h | UTC

Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring – World Health Organization

News release: WHO publishes new clinical and service delivery recommendations for HIV prevention, treatment and care

 


U.S. Guidelines panel recommendation for long-acting injectable antiretroviral regimen in adults and adolescents with HIV

28 Feb, 2021 | 20:34h | UTC

HHS Adults and Adolescents Antiretroviral Guidelines Panel Recommendation for the Long-Acting Injectable Antiretroviral Regimen of Cabotegravir and Rilpivirine – HIV.gov

What’s New in the Guidelines? Panel’s Recommendation for Long-Acting Injectable Cabotegravir and Rilpivirine in Persons with HIV

 


WHO recommends the Dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection

28 Jan, 2021 | 01:22h | UTC

WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection – World Health Organization

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.